TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

Johnson & Johnson (J&J) Innovation Medicine has submitted a request to the US Food and Drug Administration (FDA) to approve a new way of starting treatment with its drug Tremfya (guselkumab) for ...

TREMFYA ® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA ® ...

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...

"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...

Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

Furthermore, in prespecified analyses of subpopulations defined by prior advanced therapy treatment status, TREMFYA® demonstrated clinically meaningful results across all endpoints in both biologic ...

Johnson & Johnson (J&J) announced new 96-week data from the long-term extensions (LTE) of the phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of Tremfya (guselkumab) in ...

The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults. The Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . Tremfya is the first approved IL-23 inhibitor to offer both IV and fully subcutaneous induction regimens. This ...